Relay Therapeutics Shares Jump After Interim Data From Bile Duct Cancer Drug Ahead Of ESMO Presentation

• Relay Therapeutics Inc's (NASDAQ: RLAY) ReFocus trial for RLY-4008 was published on the European Society for Medical Oncology's (ESMO) website.

• The abstract has been selected for an oral presentation at the upcoming ESMO Congress 2022.

• Relay Therapeutics is evaluating RLY-4008, its bile duct cancer drug, for a narrow group of patients with FGFR2-altered cholangiocarcinoma.

• Related: Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial.

• Potent efficacy was observed across all doses, particularly at the recommended phase 2 dose (RP2D) of 70mg QD with an objective response rate of 88%.

• One patient treated at the RP2D had a near-complete response and subsequent tumor resection with curative intent.

• DOR is not yet mature, with the majority of responses ongoing.

• Across all doses (N=195), the most common treatment-related AEs (TRAEs) were low-grade stomatitis (48%), PPE (46%), and dry mouth (31%). No grade 4/5 TRAEs were observed.

• Price Action: RLAY shares are up 19.50% at $30.30 on the last check Thursday.

See more from Benzinga

• Alnylam Shares Detailed Patisiran Data From Rare Disease Study

• After Initial Skepticism FDA's Adcomm Backs Amylyx's Amyotrophic Lateral Sclerosis Hopeful

• Tesla Motors (TSLA) – If You Invested $100 When Elon Musk First Tweeted About Dogecoin, Here's How Much Y

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.